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Introduction: Retroperitoneal fibrosis is a rare disease. It can be primary (Ormond’s disease) 
or secondary to inflammation, malignancy or some drugs. Beta-adrenergic blockers including 
propranolol can cause the retroperitoneal fibrosis disease. 
Case: A 44-year-old woman who was taking propranolol for 13 years came to our center with complaints of oliguria and uremia symptoms (malaise, nausea and vomiting). After some 
investigations, it was found that the disease was retroperitoneal fibrosis. In the first step, she was 
treated with corticosteroids and then because of inadequate response, bilateral ureterolysis was 
performed. Then, an additional course of corticosteroid therapy was required after surgery.  
Conclusion: Retroperitoneal fibrosis is an unknown cause disease that can involve ureters and 
can cause obstructive symptoms. The imaging procedure of choice for diagnosis is abdominal 
CT scanning with oral and intravenous contrast agents. Corticosteroids are the first option for 
treatment, however, if they are not effective and in case of severe obstruction, ureterolysis can be 
performed. Beta- adrenergic blocker drugs that are widely used in heart diseases can be a cause 
of retroperitoneal fibrosis.
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Implication for health policy/practice/research/medical education:
Retroperitoneal fibrosis is an unknown cause disease that can involve ureters and cause obstructive symptoms. The useful imaging 
method for diagnosis retroperitoneal fibrosis is abdominal CT scanning with oral and intravenous contrast agents. Corticosteroids 
are the first option for treatment. However, if they were not effective and in cases of severe obstruction, ureterolysis can be performed. 
Beta-adrenergic blocker drugs that are widely used in heart diseases can be a cause of retroperitoneal fibrosis.   
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Introduction
Retroperitoneal fibrosis is characterized by the 
proliferation of fibrous tissue in the retroperitoneal space. 
It may occur as a primary idiopathic retroperitoneal fibrosis 
(Ormond’s disease) or as a secondary disease in response 
to inflammation, malignancy, drugs, surgery, infection or radiation therapy (1,2). 
Retroperitoneal fibrosis is an uncommon condition with an 
estimated incidence of 1.38 cases per 100,000 people (1-3). 
Its peak prevalence is observed in the 40-60 years of age 
and the ratio of male to female is reported to be 2 to 1 (4,5). 
The probability of an allergic or autoimmune mechanism 
has been put forward for this disease. Fibrosis usually 
occurs around the abdominal aorta and iliac vessels below 
the renal arteries (2).The main characteristic and also main complication of this disease is asymptomatic and progressive involvement of ureters (2). Different drugs that have been noted to 
cause idiopathic fibrosis include: ergotamine, propranolol, 
methysergid, hydralazin, methyldopa, metoprolol and some analgesics. 
CaseThe patient was a 44-year-old woman, a known case 
hypothyroidism who has been under treatment with 
levothyroxine, propranolol, and clonazepam since 13 years ago. The patient was referred to the emergency ward, with uremia symptoms (weakness, nausea and vomiting) and 
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oliguria. In the preliminary management, the patient was 
placed under hemodialysis treatment due to high blood 
urea nitrogen and creatinine (BUN=112 mg/dl, Cr=10 
mg/dl), electrolyte imbalance (K=6.5 mg/dl) and uremia 
symptoms. Patient stated a history of vague abdominal pain since the last year. In paraclinical evaluations, conducted 
during hospitalization, patient suffered with chronic 
anemia (Hemoglobin=9.8 g/dl) as well, bilateral fullness of pelvicalyceal system was reported on ultrasonography of the 
kidneys. In the next phase, spiral abdominopelvic CT-scan without intravenous contrast was performed that showed 
bilateral mild hydronephrosis. Moreover, a dense fibrotic 
plaque was observed, surrounding the central abdominal vessels. JJ stents were placed for the patient in the ureters 
on both sides, since, it was suspected inflammatory process 
surrounding the ureters and considered the probability of 
the two-sided obstructive factor led to increased creatinine 
and oliguria. After JJ stent insertion, diuresis was established 
and BUN/Cr decreased. The patient did not require dialysis 
anymore. The medial deviation was clearly observed in 
both ureters after placing stents on KUB. Propranolol was stopped; the patient was left out with prescription of corticosteroid drugs (prednisolone 50 mg daily). After 5 
weeks, patient’s stents were removed. However, anuria occurred and creatinine increased. Stents were placed in 
both ureters and diuresis established again. After 3 weeks, 
despite corticosteroid therapy and ureteral catheterization 
oliguria and rising in BUN/Cr occurred. Thus, the patient was candidate for surgery. Ureterolysis was done and ureters were placed in peritoneum.
Samples obtained from the fibrotic tissues and were sent 
to the pathology laboratory, however, no evidence of malignancy was found. After the fourth week, JJ catheters 
were removed, but the patient showed a gradual increase in 
creatinine level after about a week (1.2 to 3.1). Two options 
were proposed for the patient’s management. One of them 
was inserting ureteral stents again or beginning treatment with corticosteroid that the second option was adopted. 
Serum creatinine was declined to 1.5 mg/dl and remained 
constant after consumption of prednisolone 50 mg/day. After one month of treatment, drug tapered gradually and was interrupted after 4 months. After 6 months of follow- 
up, patient had not any complaint and serum BUN/Cr levels remained constant. 
Discussion  
Retroperitoneal fibrosis is a rare cause of renal failure with a 
silent clinical course.  Early inflammatory reaction involves T 
cells (T helper), plasma cells and macrophages significantly. 
Then, these cells are replaced with the collagen synthesizing 
fibroblasts subsequently (1). The retroperitoneal fibrosis 
process begins right from below the renal artery. Fibrosis develops gradually and surrounds ureters, inferior vena cava, aorta and mesenteric vessels or sympathetic 
nerves. Bilateral involvement was reported in 67% of 
cases. Retroperitoneal fibrosis can also be secondary to a 
variety of inflammatory situations or be allergic reactions 
to medications. These inflammatory conditions include 
abdominal aortic aneurysm, pancreatitis, histoplasmosis, 
tuberculosis and actinomycosis. Retroperitoneal fibrosis 
can also be related to a variety of malignancies including 
prostate, pancreas and stomach cancers. It can be associated 
with non-Hodgkin lymphoma, stromal and carcinoid tumors, 
too. Retroperitoneal fibrosis has been seen with some autoimmune diseases, including ankylosing spondylitis, 
systemic lupus erythematous, Wegener’s granulomatosis, and polyarteritis nodosa (1,6). The primary symptoms 
include a dull and non-localized pain in the flanks, back 
and abdomen (6,7). The pain is usually associated with 
weakness, anorexia, weight loss, fever, back pain and high 
blood pressure. In the next stage of the disease, symptoms 
occur due to obstructive uropathy and azotemia (8). Microscopic hematuria and anuria may occur (9,10).   
Early diagnosis of retroperitoneal fibrosis is possible, using imaging studies. The classic diagnostic triad in excretory urography include hydroureteronephrosis in proximal parts of the ureters, medial deviation of the ureters, and the evidence of external pressure on them (4,7,8). A long  segment 
of ureters  usually involves and absence of peristalsis due 
to fibrosis in some cases is led to pipe stem appearance (11). Laboratory evaluation may show an increase of 
BUN and creatinine or erythrocyte sedimentation rate 
(ESR).  At present, abdominopelvic CT-scan with oral and intravascular contrast agents is the useful imaging method 
for diagnosis and shows the size and extent of the fibrotic process generally. If renal function is compromised, MRI can 
be a helpful imaging procedure (1). Although some cases of 
spontaneous regression have been reported, treatment of this disease is usually surgical. A course of corticosteroid 
therapy may be tried first and obtains favorite results in some cases. If the patient fails to respond to corticosteroid 
or in cases with sever obstruction and increase creatinine 
level, such as in our patient, it will be necessary to separate 
ureters from fibrotic plaque with surgery.  After releasing 
the ureters, they are wrapped with omentum or brought to an intraperitoneal location to prevent their recurrence (11). Demko and colleagues reported a patient with an increase 
in blood pressure and the progressive renal insufficiency. 
After confirming the diagnosis of retroperitoneal fibrosis 
by radiographic studies, the patient underwent ureterolysis surgery and this caused a creatinine decrease (3). There was a difference in our patient in spite of ureterolysis treatment. There was a gradual increase in creatinine level that led to starting corticosteroid therapy again. In another case, 
reported by Skehan et al., a patient with retroperitoneal 
fibrosis due to metoprolol was treated by ureterolysis (12). 
The success rate of ureterolysis operation has been reported 
to be between 66-100%. Most of physicians discontinue 
medical treatment after surgery and a few prescribe medical therapies with corticosteroids or other immunosuppressive 
drugs. In a study performed by Jung et al. on 27 patients 
with fibrosis of the retroperitoneum, the use of immune 
suppressive therapy like glucocorticoid and azathioprine 
reduced acute phase proteins and decreased the fibrotic 
mass size in most patients (2). There is no identical opinion 
about medical treatment and the dose and duration of treatment yet (13). After removal of stents in this patient, we had to administer corticosteroid due to a creatinine rise, 
and obtained a suitable response. This finding reveals that, it is necessary to care patient after surgery carefully. In cases of returning symptoms, at least, the use of corticosteroids can help in some patients.
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Clinical use of beta-blockers is widespread. Beneficial effects of this drug on cardiovascular system especially at hypertension, angina and arrhythmia is very important and popular. The treatment of chronic congestive heart failure is a new application for this drug (14). Since the beta blocker 
medications use in high level to treat high blood pressure 
and angina, some cases of idiopathic fibrosis inevitably be 
attributed to the use of these drugs (12).
Conclusion
Retroperitoneal fibrosis is an unknown cause disease that 
can involve, ureters, and can cause obstructive symptoms. The imaging procedure of choice for diagnosis it is 
abdominal CT scanning with oral and intravenous contrast 
agents. Corticosteroids are the first option for treatment, if they could not yield optimal response, and in cases of severe 
obstruction, ureterolysis can be performed. Beta- adrenergic 
blocker drugs that are widely used in heart diseases can be a 
cause of retroperitoneal fibrosis. 
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